The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma
Year: 2022
Type: article
Source: Blood
Institutions: Mayo Clinic, Emory University, Winship Cancer Institute, Hackensack Meridian Health, The University of Texas Southwestern Medical Center, University of Michigan, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Multiple Myeloma Research Foundation, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310125472